ArticleClinical case reports2025
Drug-Induced Acrocyanosis: Highlighting Venlafaxine as a Potential Culprit.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antisynthetase Syndrome Mimicking Pulmonary Infection: A Diagnostic Lesson From County-Managed Hospital.Clinical case reports · 2026Article
- Drug-Induced Acrocyanosis: Highlighting Venlafaxine as a Potential Culprit.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acrocyanosis is a peripheral vascular disorder characterized by bluish discoloration of the distal extremities. While drug-induced acrocyanosis has been associated with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and other medications, venlafaxine has not previously been reported as a causative agent. We present a case of a 40-year-old female who developed acute acrocyanosis following the initiation of venlafaxine for insomnia. Symptoms appeared within 24 h of intake and progressively involved the hands and feet. Laboratory investigations were largely unremarkable, and other potential causes, including Raynaud's phenomenon and vasculitis, were excluded. Discontinuation of venlafaxine led to complete resolution of symptoms within a week, confirming a strong temporal association. This case underscores the need for clinical awareness of venlafaxine-induced acrocyanosis as a rare but possible adverse effect, emphasizing timely recognition and management to prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.